Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy

Redox Biology

Volumn 14, Issue , 2018, Pages 522-534

  Cuadrado, Antonio ^a,b   Kügler, Sebastian ^c   Lastres Becker, Isabel ^a,b  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

DMF; Inflammation; Neurodegeneration; NRF2; Oxidative stress; TAU GSK 3

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CALBINDIN 1; FUMARIC ACID DIMETHYL ESTER; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; KELCH LIKE ECH ASSOCIATED PROTEIN 1; TAU PROTEIN; TRANSCRIPTION FACTOR NRF2; NEUROPROTECTIVE AGENT; NFE2L2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; ASTROCYTOSIS; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EMBRYO; ENZYME ACTIVITY; FIBROBLAST; MICROGLIA; MOUSE; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PI3K AKT GSK 3 SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RIGHT HIPPOCAMPUS; SIGNAL TRANSDUCTION; TAUOPATHY; TREATMENT DURATION; VALIDATION PROCESS; ANIMAL; DISEASE MODEL; DRUG EFFECT; METABOLISM; MOLECULARLY TARGETED THERAPY; OXIDATIVE STRESS;

ANIMALS; DIMETHYL FUMARATE; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; MICE; MOLECULAR TARGETED THERAPY; NEUROPROTECTION; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; TAUOPATHIES;

EID: 85032830661     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2017.10.010     Document Type: Article

References (41)

1. Lee, G., Leugers, C.J., Tau and tauopathies. Progress. Mol. Biol. Transl. Sci. 107 (2012), 263–293.
2. Karakaya, T., Fusser, F., Prvulovic, D., Hampel, H., Treatment options for tauopathies. Curr. Treat. Options Neurol. 14:2 (2012), 126–136.
3. Medina, M., Garrido, J.J., Wandosell, F.G., Modulation of GSK-3 as a therapeutic strategy on tau pathologies. Front. Mol. Neurosci., 4, 2011, 24.
4. Rojo, A.I., Sagarra, M.R., Cuadrado, A., GSK-3beta down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J. Neurochem. 105:1 (2008), 192–202.
5. Rushmore, T.H., Morton, M.R., Pickett, C.B., The antioxidant responsive element. activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J. Biol. Chem. 266:18 (1991), 11632–11639.
6. Hayes, J.D., Dinkova-Kostova, A.T., The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci. 39:4 (2014), 199–218.
7. Espinosa-Diez, C., Miguel, V., Mennerich, D., Kietzmann, T., Sanchez-Perez, P., Cadenas, S., Lamas, S., Antioxidant responses and cellular adjustments to oxidative stress. Redox Biol. 6 (2015), 183–197.
8. Rada, P., Rojo, A.I., Chowdhry, S., McMahon, M., Hayes, J.D., Cuadrado, A., SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol. Cell. Biol. 31:6 (2011), 1121–1133.
9. Rojo, A.I., Rada, P., Egea, J., Rosa, A.O., Lopez, M.G., Cuadrado, A., Functional interference between glycogen synthase kinase-3 beta and the transcription factor Nrf2 in protection against kainate-induced hippocampal cell death. Mol. Cell. Neurosci. 39:1 (2008), 125–132.
10. Salazar, M., Rojo, A.I., Velasco, D., de Sagarra, R.M., Cuadrado, A., Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J. Biol. Chem. 281:21 (2006), 14841–14851.
11. Lastres-Becker, I., Garcia-Yague, A.J., Scannevin, R.H., Casarejos, M.J., Kugler, S., Rabano, A., Cuadrado, A., Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease. Antioxid. Redox Signal. 25:2 (2016), 61–77.
12. Bomprezzi, R., Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview. Ther. Adv. Neurol. Disord. 8:1 (2015), 20–30.
13. Lau, A., Tian, W., Whitman, S.A., Zhang, D.D., The predicted molecular weight of Nrf2: it is what it is not. Antioxid. Redox Signal. 18:1 (2013), 91–93.
14. McCubrey, J.A., Lahair, M.M., Franklin, R.A., Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid. Redox Signal. 8:9–10 (2006), 1775–1789.
15. Hur, E.M., Zhou, F.Q., GSK3 signalling in neural development. Nat. Rev. Neurosci. 11:8 (2010), 539–551.
16. Lastres-Becker, I., Innamorato, N.G., Jaworski, T., Rabano, A., Kugler, S., Van Leuven, F., Cuadrado, A., Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis. Brain: a J. Neurol. 137:Pt 1 (2014), 78–91.
17. Jo, C., Gundemir, S., Pritchard, S., Jin, Y.N., Rahman, I., Johnson, G.V., Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52. Nat. Commun., 5, 2014, 3496.
18. Pajares, M., Jimenez-Moreno, N., Garcia-Yague, A.J., Escoll, M., de Ceballos, M.L., Van Leuven, F., Rabano, A., Yamamoto, M., Rojo, A.I., Cuadrado, A., Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes. Autophagy 12:10 (2016), 1902–1916.
19. Williamson, R., van Aalten, L., Mann, D.M., Platt, B., Plattner, F., Bedford, L., Mayer, J., Howlett, D., Usardi, A., Sutherland, C., et al. CRMP2 hyperphosphorylation is characteristic of Alzheimer's disease and not a feature common to other neurodegenerative diseases. J. Alzheimer's Dis. 27 (2011), 615–625.
20. Iritani, S., Niizato, K., Emson, P.C., Relationship of calbindin D28K-immunoreactive cells and neuropathological changes in the hippocampal formation of Alzheimer's disease. Neuropathol.: Off. J. Jpn. Soc. Neuropathol. 21:3 (2001), 162–167.
21. Jiao, S.S., Shen, L.L., Zhu, C., Bu, X.L., Liu, Y.H., Liu, C.H., Yao, X.Q., Zhang, L.L., Zhou, H.D., Walker, D.G., et al. Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer's disease. Transl. Psychiatry, 6(10), 2016, e907.
22. Sanchez-Guajardo, V., Febbraro, F., Kirik, D., Romero-Ramos, M., Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One, 5(1), 2010, e8784.
23. Rojo, A.I., Innamorato, N.G., Martin-Moreno, A.M., De Ceballos, M.L., Yamamoto, M., Cuadrado, A., Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 58:5 (2010), 588–598.
24. An, Y.W., Jhang, K.A., Woo, S.Y., Kang, J.L., Chong, Y.H., Sulforaphane exerts its anti-inflammatory effect against amyloid-beta peptide via STAT-1 dephosphorylation and activation of Nrf2/HO-1 cascade in human THP-1 macrophages. Neurobiol. Aging 38 (2016), 1–10.
25. Kanninen, K., Malm, T.M., Jyrkkanen, H.K., Goldsteins, G., Keksa-Goldsteine, V., Tanila, H., Yamamoto, M., Yla-Herttuala, S., Levonen, A.L., Koistinaho, J., Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Mol. Cell. Neurosci. 39:3 (2008), 302–313.
26. Wruck, C.J., Gotz, M.E., Herdegen, T., Varoga, D., Brandenburg, L.O., Pufe, T., Kavalactones protect neural cells against amyloid beta peptide-induced neurotoxicity via extracellular signal-regulated kinase 1/2-dependent nuclear factor erythroid 2-related factor 2 activation. Mol. Pharmacol. 73:6 (2008), 1785–1795.
27. von Otter, M., Landgren, S., Nilsson, S., Zetterberg, M., Celojevic, D., Bergstrom, P., Minthon, L., Bogdanovic, N., Andreasen, N., Gustafson, D.R., et al. Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract. Mech. Ageing Dev. 131:2 (2010), 105–110.
28. Lei, P., Ayton, S., Bush, A.I., Adlard, P.A., GSK-3 in neurodegenerative diseases. Int. J. Alzheimer's. Dis., 2011, 2011, 189246.
29. Cuadrado, A., Martin-Moldes, Z., Ye, J., Lastres-Becker, I., Transcription factors NRF2 and NF-kappaB are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation. J. Biol. Chem. 289:22 (2014), 15244–15258.
30. Innamorato, N.G., Lastres-Becker, I., Cuadrado, A., Role of microglial redox balance in modulation of neuroinflammation. Curr. Opin. Neurol. 22:3 (2009), 308–314.
31. Lastres-Becker, I., Ulusoy, A., Innamorato, N.G., Sahin, G., Rabano, A., Kirik, D., Cuadrado, A., Alpha-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Human. Mol. Genet. 21:14 (2012), 3173–3192.
32. Heizmann, C.W., Braun, K., Changes in Ca(2+)-binding proteins in human neurodegenerative disorders. Trends Neurosci. 15:7 (1992), 259–264.
33. Schmidt, H., Three functional facets of calbindin D-28k. Front. Mol. Neurosci., 5, 2012, 25.
34. Yenari, M.A., Minami, M., Sun, G.H., Meier, T.J., Kunis, D.M., McLaughlin, J.R., Ho, D.Y., Sapolsky, R.M., Steinberg, G.K., Calbindin d28k overexpression protects striatal neurons from transient focal cerebral ischemia. Stroke 32:4 (2001), 1028–1035.
35. Finkbeiner, S., Calcium regulation of the brain-derived neurotrophic factor gene. Cell. Mol. Life Sci. 57:3 (2000), 394–401.
36. Jazwa, A., Rojo, A.I., Innamorato, N.G., Hesse, M., Fernandez-Ruiz, J., Cuadrado, A., Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid. Redox Signal. 14:12 (2011), 2347–2360.
37. Schulze-Topphoff, U., Varrin-Doyer, M., Pekarek, K., Spencer, C.M., Shetty, A., Sagan, S.A., Cree, B.A., Sobel, R.A., Wipke, B.T., Steinman, L., et al. Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc. Natl. Acad. Sci. USA 113:17 (2016), 4777–4782.
38. López González, I., Garcia-Esparcia, P., Llorens, F., Ferrer, I., Genetic and transcriptomic profiles of inflammation in neurodegenerative diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and tauopathies. Int. J. Mol. Sci., 17(2), 2016, 206.
39. Li, Y., Liu, L., Barger, S.W., Griffin, W.S.T., Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci.: Off. J. Soc. Neurosci. 23:5 (2003), 1605–1611.
40. Sheng, J.G., Zhu, S.G., Jones, R.A., Griffin, W.S.T., Mrak, R.E., Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp. Neurol., 163(2), 2000, 10.1006/exnr.2000.7393.
41. Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.M., Iwata, N., Saido, T.C., Maeda, J., Suhara, T., Trojanowski, J.Q., Lee, V.M., Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53:3 (2007), 337–351.